As early as next week, Moderna will start its first clinical trial of a new crown candidate vaccine against the mutant virus. The experiment will be conducted at five research sites in the United States.The main purpose of this study was to evaluate the safety and efficacy of mrna-1273 and mrna-1273.351 vaccines, and the secondary purpose was to evaluate the antibody mediated immunity of mrna-1273 and mrna-1273.351 vaccines.
It is understood that Moderna announced in February that it has completed the clinical trial dose manufacturing of specific candidate vaccine mrna-1273.351 for b.1.351 (also known as 501y.v2) new coronal mutant virus first found in South Africa.
The company recently said it had agreed to supply 13 million doses of the vaccine to the Philippine government, starting in mid-2021. The company is also expected to reach a separate agreement with the Philippine government and the private sector to provide another 7 million doses of vaccine.